Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06843551 · ClinicalTrials.gov registry record · Phase 2
The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation
A Phase 2 study of Metastatic Pancreatic Cancer and Metastatic Pancreatic Ductal Adenocarcinoma, sponsored by Benjamin Spieler.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06843551 is a Phase 2 study of Metastatic Pancreatic Cancer and Metastatic Pancreatic Ductal Adenocarcinoma that is actively recruiting participants, run by Benjamin Spieler. The registered enrollment target is 20 participants, below the 106-participant average among 32 other Metastatic Pancreatic Cancer trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06843551, a Phase 2 study of Metastatic Pancreatic Cancer and Metastatic Pancreatic Ductal Adenocarcinoma, is actively recruiting participants, sponsored by Benjamin Spieler.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess if radiation therapy (which uses high-energy radiation to damage or destroy cancer cells) combined with immune checkpoint inhibitors (medications that helps the body recognize and attack cancer cells) will be beneficial for patients with metastatic pancreatic ductal adenocarcinoma.
Conditions Studied
Interventions
- RADIATION Stereotactic Body Radiation Therapy
- DRUG Balstilimab
- DRUG Botensilimab
Study Locations (1)
Florida
- University of Miami - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-06-18 |
| Est. Completion | 2030-08-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06843551
The ClinicalTrials.gov registry entry for NCT06843551 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 106-participant average among 32 other Metastatic Pancreatic Cancer trials with a reported enrollment target (81% lower). The listed sponsor is Benjamin Spieler, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastatic Pancreatic Cancer appearing as the primary indexed condition, and to 3 interventions - of which Stereotactic Body Radiation Therapy is the first listed.
NCT06843551 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT06843551 about?
NCT06843551 is a clinical study titled "The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation". The purpose of this study is to assess if radiation therapy (which uses high-energy radiation to damage or destroy cancer cells) combined with immune checkpoint inhibitors (medications that helps the body recognize and attack cancer cells) will be beneficial for patients with metastatic pancreatic d...
What is the current status of trial NCT06843551?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2025-06-18. Estimated completion is 2030-08-01.
What conditions does trial NCT06843551 study?
This clinical trial studies the following conditions: Metastatic Pancreatic Cancer, Metastatic Pancreatic Ductal Adenocarcinoma.
What interventions are being tested in trial NCT06843551?
The interventions under investigation include: Stereotactic Body Radiation Therapy (RADIATION), Balstilimab (DRUG), Botensilimab (DRUG).
Who is sponsoring clinical trial NCT06843551?
This trial is sponsored by Benjamin Spieler, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06843551 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
RECRUITING · Phase 2
-
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
RECRUITING · Phase 2
-
Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.
RECRUITING · Phase 2
-
Proglumide and Chemotherapy for Metastatic Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Metastatic Pancreatic Cancer
All registered trials for this condition
Metastatic Pancreatic Ductal Adenocarcinoma
All registered trials for this condition
Florida
All trials with a study site in Florida
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.